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ABSTRACT
Cord blood (CB) natural killer (NK) and lymphokine-activated killer (LAK) cytotoxic cells are poorly charac-
terized but might be used to treat minimal residual and/or recurrent malignant disease. Currently, there is no
mechanism to use CB for adoptive cancer cellular immunotherapy after CB transplantation (CBT). Recog-
nizing this as a deficiency, we hypothesized that CB aliquots could be engineered ex vivo for potential donor
lymphocyte infusion after CBT. Cryopreserved CB aliquots were thawed, depleted of monocytes, and cultured
in serum-free medium alone or serum-free medium with anti-CD3 and interleukins 2, 7, and 12 combined with
antibody/cytokines for 48 hours. Immunophenotyping, cytotoxicity, and proliferation were evaluated. A sig-
nificant expansion of CD3 was seen, in addition to increases in lymphocyte subsets of CD8, CD8/CD25,
and CD3/45RO versus medium alone. A significant enhancement of CD3 proliferation (P < .001), NK
cytotoxicity, NK subset expansion, LAK cytotoxicity, and T-helper 1 subset expansion was also demonstrated.
Significant enrichment was seen in NK CD16/CD56bright, CD16/CD56dim, CD56bright and CD56dim/
KIR3DL1, CD56bright and CD56dim/KIR2DL1, CD56bright and CD56dim/KIR2DL2 and CD94/
NKG2a subsets. These increases in CB NK subsets were in part secondary to augmentation of cell survival.
Further, survival of NOD-SCID mice xenografted with human K562 cells and treated with CB cells expanded
with antibody/cytokines was significantly higher than that in animals that received no treatment (phosphate
buffered saline) and those that were treated with CB ex vivo expanded in medium alone (P< .005, respectively).
These data suggest that cryopreserved CB cells could be ex vivo engineered for potential use as adoptive cancer
cellular immunotherapy for donor lymphocyte infusion after CBT.
© 2006 American Society for Blood and Marrow Transplantation
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uNTRODUCTION
Cryopreserved unrelated cord blood (UCB) has
een demonstrated to be an alternative allogeneic
resented in part at the American Association of Cancer Research; Or-
ando, Florida; April 2004; and the American Society of Hematology; Sanciego, California; December 2004.
08tem cell source to safely reconstitute HLA antigen-
isparate transplant recipients (children and adults)
ith a lower incidence of severe (grade III/IV) graft-
ersus-host disease [1-5]. More than 100 000 UCB
nits have been collected and cryopreserved in public
B banks throughout the world [6-8]. However, the
se of UCB as a potential source for allogeneic stem
ell transplantation (AlloSCT) is limited in part by
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Ex Vivo CB NK and LAK Lymphocytes and NK Receptors
Bmall numbers of committed hematopoietic progeni-
or cells. In addition, UCB is limited by the absence of
vailable donor effector cells (natural killer [NK] cells,
ytotoxic T lymphocytes, lymphokine-activated killer
LAK] cells, and NK T cells) for infusion after UCB
ransplantation (UCBT) for the treatment of minimal
esidual resistant hematologic malignant disease, re-
apse, and/or posttransplant lymphoproliferative dis-
ase [7-9].
CB has been ex vivo expanded to yield increased
umbers of total nucleated cells, granulocyte-mac-
ophage colony-forming cells, high proliferative po-
ential colony-forming cells, and CD34 cells that
ave been successfully engrafted in animal models
10,11]. Phase I/II studies of augmentation of standard
CBT with ex vivo expanded cells in humans have
lso been reported [12]. Several studies have demon-
trated that CB can be cryopreserved, without manip-
lation or after physical separation, without loss of
lonogenic capacity, immunophenotypic composition,
r potential for ex vivo expansion of hematopoietic
rogenitor cells [13,14].
CB immune cells have been reported to have sig-
iﬁcant antitumor activity and thus could provide the
ecessary immunocompetent cells for adoptive cancer
ellular immunotherapy (ACCI) after AlloSCT. Our
aboratory has investigated 3 cytokines, interleukin
IL) 2, IL-12, and IL-15, alone and in combination,
nd their in vitro immune-modulating effects on the
ctivity of CB mononuclear cells (MNCs) and NK and
AK cells [15-17]. We and others have also demon-
trated that CB NK and LAK cells lyse tumor blasts,
eadily respond to IL-2, IL-12, and IL-15 stimulation
nd mediate high levels of apoptotic-mediated cyto-
oxicity against target tumor cells [18,19]. CB-derived
-cell subsets and NK (CD56) cells have also been
uccessfully ex vivo expanded and maintained to en-
ance their cytotoxic potential [20,21].
NK cells have been characterized as innate im-
une lymphocytes with a capacity to lyse tumor cells
nd do not require speciﬁc antigen recognition [22].
K cells are characterized by NK receptors (NKRs)
hat inhibit or activate NK cytotoxicity [22,23]. NK
ells can be further subdivided into 2 subsets of innate
mmunoregulatory cells, including CD56bright NK
ells characterized by high expression of lectin-like
eceptors (CD94/NKG2) and low receptor NK cyto-
oxicity, and CD56dim characterized by high expres-
ion of killer immunoglobulin NKRs and enhanced
K cytotoxicity [24-26]. In addition, the main killing
echanism of NK cells is mediated by the perforin
athway by which NK cells release perforin that is
eleased from cytotoxic granules, which then facili-
ates the entry of serine proteases or granzymes from
ntracellular granules in the induction of tumor cell
poptosis [27,28].Because the cryopreserved UCB unit is usually t
B&MThawed and used in its entirety for AlloSCT, the ex
ivo generation of NK and/or LAK for UCB ACCI
fter transplantation has been nonexistent. In light of
ur previous in vitro studies of the stimulation and
ctivation of adult peripheral blood and CB NK and
AK cells with IL-2 and IL-12 alone or in combina-
ion, we investigated a novel strategy for the ex vivo
xpansion and activation of CB MNCs for potential
CCI. Our laboratory previously reported a signiﬁ-
ant enhancement by IL-7 on the proliferation, acti-
ation, maturation, and cytotoxic potential of CB T
ells from fresh and thawed CB MNCs when added ex
ivo to IL-2, IL-12, and anti-CD3 in serum-free (SF)
edium [29,30]. In this study, we hypothesized and
eveloped a method for residual CB aliquots that were
reviously cryopreserved, thawed, and ex vivo ex-
anded in short-term culture with NK and LAK ac-
ivities. We evaluated and characterized the matu-
ation, proliferative response, activation of NK and
AK T-cell subsets, expression of T-cell and NKR
ubsets, the cytolytic mechanism involved, and sub-
equent survival of NOD-SCID mice xenografted
ith human K562 cells when treated with these
ecryopreserved and rethawed ex vivo expanded
ymphocytes.
ATERIALS AND METHODS
ollection and Processing of CB
CB was obtained postpartum from the umbilical
ords of full-term healthy babies of normal vaginal
r cesarean section delivery by cannulation of the
mbilical vein and collection into a bag containing
itrate phosphate dextrose. CB was depleted of red
lood cells by hydroxyethyl starch sedimentation,
ecreased in volume, cryopreserved with dimethyl-
ulfoxide, and stored in liquid nitrogen as previously
escribed [6,7]. Maternal donor consent was obtained
efore performance of any research and the research
rotocol was approved by the institutional review board
nd performed in compliance with the Declaration of
elsinki.
NC Isolation and Cell Expansion
Cryopreserved CB was initially thawed and
ashed according to a modiﬁed method of Rubinstein
t al [31]. Brieﬂy, CB units were thawed at 37°C in
terile water for approximately 2 minutes. The CB
nit was diluted 1:1 with dextran/human serum albu-
in (HSA) (Baxter Healthcare Corporation, Deer-
eld, IL, /Bayer Corporation, Elkhart, IN) that con-
isted of 2.5% (wt/vol) serum albumin and 5% (wt/
ol) dextrose in isotonic saline and centrifuged at 400g
or 10 minutes. The supernatant was removed and
ells slowly resuspended in equal volumes of the dex-
ran/albumin wash solution. Viability was conﬁrmed
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6y trypan blue (Sigma-Aldrich, St. Louis, MO) exclu-
ion and manual cell counts were performed with a
emacytometer.
For expansion, CB cells were resuspended at 5 
06 cells/mL in serum-free lymphocyte medium
AIM-V; Invitrogen, Carlsbad, CA) plus 20 U/mL
eparin (Elkins-Sinn, Cherry-Hill, NJ) and incubated
vernight to deplete adherent monocytes. Nonadher-
nt cells were removed and cultured at 1  106
ells/mL in T25 ﬂasks (Costar, Cambridge, MA) in SF
edium alone or SF medium supplemented with an
ntibody/cytokine (AB/CY) combination for 48 hours
t 37°C in 5% carbon dioxide. The AB/CY combina-
ion consisted of 50 ng/mL anti-CD3 (R&D Systems,
inneapolis, MN), 5 ng/mL IL-2 (Peprotech, Rocky
ill, NJ), 10 ng/mL IL-7 (Peprotech), and 10 ng/mL
L-12 (Peprotech).
ryopreservation and Thawing
Three different cryopreservation/thawing modal-
ties were analyzed in this study. Each modality used
he same original CB unit. First, aliquots of cryopre-
erved CB units were thawed and expanded (CTE) as
reviously described [31]. Second, aliquots of the same
ryopreserved CB units were thawed and expanded as
escribed above and then recryopreserved and re-
hawed (CTECT) by using a similar cryopreservation
nd thawing method. Third, aliquots of the same
ryopreserved CB units were thawed, recryopre-
erved, rethawed, and expanded (CTCTE). Recryo-
reservation was performed according to the method
f the National Heart, Lung and Blood Institute/Cord
lood Transplantation Study [6]. Brieﬂy, expanded
B cell fractions or CB aliquots previously cryopre-
erved and thawed were cryopreserved in chilled
0% dimethylsulfoxide (Cryoserv, Research Indus-
ries, Salt Lake City, UT) with 5% (wt/vol) dextran
0 (Baxter Fenwal Healthcare, Irvine, CA). The
ryoprotectant and cell fractions were transferred
nto Cryocyte freezing bags (Baxter Immunother-
py, Irvine, CA), placed into aluminum canisters,
eposited horizontally in a controlled-rate freezer
Cryomed, Marietta, OH) until 85°C was reached,
nd transferred to liquid nitrogen (196°C) for
hort-term storage.
roliferation
Proliferation was assessed as previously described
y tetrazolium degradation of WST-1 as determined
ith a standard kit (Roche Diagnostics Corporation,
ndianapolis, IN) [30]. Brieﬂy, 10 L of WST-1 dye
as added to 100 L of the CB MNC expanded
ultures (CTE, CTECT, or CTCTE) at 2  104
ells/mL in a 96-well ﬂat-bottom plate (Costar) and
ncubated for 3 hours. The plate was shaken for 1 c
10inute and absorbance was read at 550 nm by a plate
eader (Beckman-Coulter, Hialeah, FL).
-Cell, NK, and LAK Subsets
CTE, CTECT, and CTCTE cells (5  105) were
ashed in phosphate buffered saline (PBS) supple-
ented with 10% heat-inactivated fetal bovine serum
Sigma-Aldrich) and 1% sodium azide (Sigma-Aldrich).
luorescent conjugated monoclonal antibodies (CD3,
D8, CD16, CD25, CD56, or CD45RO; BD Bio-
ciences, San Diego, CA) were added and cells of the
different modalities were incubated in the dark at
°C for 20-30 minutes, washed in azide buffer, and
xed with .5% paraformaldehyde (Sigma-Aldrich).
ppropriate isotype controls were included in each
xperiment. Samples were analyzed on a BD FACS-
alibur (BD Biosciences) using CellQuest software.
he lymphocyte subpopulation of the CD45 popu-
ation was gated and used as a reference for determi-
ation of CD3, CD8, CD16, CD25, CD56, or
D45RO populations. A minimum of 10 000 events
as collected for each evaluation.
KR Expression
The expanded populations (CTE, CTECT, or
TCTE) were analyzed for phenotypic expression
f NK subsets (CD94) and NKRs (KIR3DL1,
IR2DL1/S1, KIR2DL2, and NKG2a). In brief,
TE, CTECT, and CTCTE cells (5  105 cells)
ere washed in PBS supplemented with 10% heat-
nactivated fetal bovine serum (Sigma-Aldrich) and
% sodium azide (Sigma-Aldrich). Fluorescent conju-
ated monoclonal antibodies (CD16, CD56, NKBL1,
D158a, CD158b, CD94, or NKG2a; BD Biosciences
nd Beckman-Coulter) were added and cells were in-
ubated in the dark at 4°C for 20-30 minutes, washed
n azide buffer, and ﬁxed with .5% paraformaldehyde
Sigma-Aldrich). Appropriate isotype controls were
ncluded in each experiment. Samples were analyzed
n a BD FACSCalibur (BD Biosciences) using
ellQuest software. NK cells were selected based on
heir CD3/CD16/CD56 phenotype and the pro-
ortions of CD56dim and CD56bright NK cells within
he CD16/CD56 NK cell compartment were cal-
ulated. Each NK cell subset was then separately an-
lyzed for its light scatter and forward side scatter
haracteristics and expression of the surface antigens
ecognized by the monoclonal antibodies mentioned
bove [32,33]. A minimum of 10 000 events was col-
ected for evaluation.
-Helper 1 Subset Analysis (Intracellular
nterferon )
Intracellular interferon  (IFN-) analysis was
erformed with a ﬂuorescein isothiocyanate (FITC)–
onjugated monoclonal antibody speciﬁc for IFN- as
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Ex Vivo CB NK and LAK Lymphocytes and NK Receptors
Breviously described [30]. Brieﬂy, 1.8  106 expanded
B MNCs (CTE, CTECT, or CTCTE) were pre-
reated with 12 L of Golgi Stop (BD Biosciences) for
hours and stained for extracellular CD3. Next cells
ere ﬁxed and permeabilized with Cytoﬁx/Cytoperm
eagent kit (BD Biosciences), incubated with IFN-/
ITC monoclonal antibody (BD Biosciences), washed,
nd ﬁxed in .5% paraformaldehyde. Control samples
ere stained only for CD3 and not permeabilized or
tained with the IFN-/FITC monoclonal antibody.
ppropriate isotype controls were used for each ex-
eriment. All samples were analyzed within 24 hours
y ﬂow cytometry. The gated CD3 population
erved as a reference for the determination of intra-
ellular IFN-, and a minimum of 10 000 events was
ollected.
K and LAK Cytotoxicity
NK and LAK cellular cytotoxicity was determined
y metabolization of the yellow tetrazolium salt [3-(4,5-
imethylthiazil-2-yl)-2,5-diphenyl tetrazolium bromide]
r resazurin as determined with a standard kit (Roche
iagnostics, Indianapolis, IN; Molecular Probes, Eu-
ene, OR) as previously described [30]. NK activity
as measured against K562 target cells (sensitive to
K cells, a human erythroleukemic cell line; ATCC,
anassas, VA), whereas LAK activity was measured
gainst Daudi target cells (sensitive to LAK cells, a
uman B-lymphoblastic cell line; ATCC).
Tumor targets were resuspended in cytotoxic
-lymphocyte medium (Iscove medium, Invitrogen)
ith 5% fetal calf serum (Sigma-Aldrich), l-glutamine
Invitrogen) and Penn/Strep 5 mL of sulﬁnpyrazone
olution (Sigma-Aldrich; .7 g sulﬁnpyrazone in 150
L of PBS). Target cells were resuspended at a ﬁnal
oncentration of 1  105 cells/mL. Target cells were
ransferred to wells of 96-well U-bottom culture
lates (Costar) and effector cells (CB nonadherent
xpanded MNCs; CTE, CTECT, or CTCTE modal-
ty) were added at a 20:1 effector-to-target ratio. Con-
rol wells contained 100 L of target cells and effector
ells only. The 3-(4,5-dimethylthiazil-2-yl)-2,5-diphenyl
etrazolium bromide or resazurin was added to each
ell and plates were incubated for 1-4 hours at 5%
O2 at 37°C, shaken for 1 minute, and absorbance
as read at 550 nm by a plate reader (Beckman-
oulter). Cytotoxicity percentage was calculated
ased on the method of Niu et al [34].
ranzyme and Perforin Expression
Perforin and granzyme B analysis was performed
ith FITC anti-granzyme B (BD Biosciences) and
-phycoerythrin (PE) anti-perforin (BD Biosciences)
onjugated monoclonal antibody. In brief, CTECT
ells were incubated with K562 cells at a 20:1 effector-
o-target ratio and incubated for 4-5 hours at 37°C 1
B&MTnd 5% carbon dioxide. At the end of incubation cells
ere ﬁxed, permeabilized with a Cytoﬁx/Cytoperm
eagent kit (BD Biosciences) as previously described,
ncubated separately with anti-granzyme B (FITC)
nd anti-perforin (PE), washed, and ﬁxed in 1% para-
ormaldehyde. Appropriate isotype controls were in-
luded in all experiments. All samples were analyzed
n a FACScan ﬂow cytometer (BD Biosciences), a
inimum of 10 000 events was collected, and Pro-
uest software was used for analysis.
easurement of Viability and Cell Survival
Viability was assessed by trypan blue viability. The
ercentage of apoptotic cells was assessed with an
nnexin V-FITC/propidium iodide (PI) apoptosis de-
ection kit (BD Biosciences). Brieﬂy, 1  106 ex-
anded cells were washed in cold PBS and resus-
ended in binding buffer, and 1  105 cells were
ncubated with annexin V-FITC and PI for 15 min-
tes at room temperature in the dark. Binding buffer
as added and cells were analyzed on a FACSCalibur
BD Biosciences) ﬂow cytometer using ProQuest soft-
are. A minimum of 10 000 events was collected. Viable
ells or nonapoptotic cells were determined as annexin V
nd PI negative, whereas cells considered in early apo-
tosis were annexin V positive and PI negative.
n Vivo Cytotoxicity Studies—Animal and Human
umor Cells
We used a NOD/SCID mouse model to deter-
ine the in vivo effects of the ex vivo expanded CB
ononuclear cells. NOD/SCID male mice (Jackson
abs, Bar Harbor ME) 3-4 weeks of age were kept
nder pathogen-free conditions and all food, water,
nd bedding were autoclaved before use. Tumor
ells were represented by the human leukemia cell
ine K562 (ATCC, Manchester, VA) and cultured
nd maintained in RPMI-1640 with 10% fetal calf
erum.
ransplantation and Growth of Human Tumors in
OD/SCID Mice
Mice were ﬁrst irradiated with 350 cGy, and after
4 hours mice received subcutaneous injections of
562 cells at 10 106 tumor cells/mouse as described
y Multhoff et al [35]. Brieﬂy, 3 days after tumor cell
njection, groups of NOD/SCID mice (n  10) re-
eived intraperitoneal injections of ex vivo expanded
TECT CB cells cultured in medium alone or in
B/CY initially at concentrations of 5  106 cells/
nimal. In subsequent experiments, groups of animals
n  10) received CB cells (1  107 cells/animal)
timulated with medium alone or CB cells (1  107
ells/animal) stimulated with AB/CY. Parallel sham
njections of sterile PBS served as a control group (n
0). Injections of ex vivo expanded CB cells or PBS
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6ontinued every 7 days for 14 days. Tumor engraft-
ent/progression was determined by ﬂow cytometry
o measure human CD45 expression in peripheral
lood samples drawn weekly. Probability of survival
as determined by the Kaplan-Meier method. Ani-
als were sacriﬁced when they become moribund
ith disseminated tumor burden as directed by the
rotocol approved by the Institutional Animal Care
nd Use Committee (IACUC).
tatistics
Results are expressed as mean  SEM of 3-7
eparate experiments, and the probability of signiﬁ-
ant differences when comparing multiple treatment
roups was determined by analysis of variance fol-
owed by the Student-Newman-Keuls multiple range
est. Probability of survival in animal studies was de-
ermined by the Kaplan-Meier method. Statistical
nalyses were performed with Instat (Graph Pad, San
iego, CA). P values .05 were considered statisti-
ally signiﬁcant.
ESULTS
D3 Subset Expansion
CD3 T cells are often used as a marker for donor
ymphocyte infusion (DLI) after AlloSCT. Therefore,
e evaluated CD3 subset expansion after ex vivo
ngineering in medium or AB/CY. A signiﬁcant in-
rease (	20-fold) in the CD3 population in CTE,
TCTE, and CTECT cells was seen after 48 hours
f culture in AB/CY compared with medium alone
7.37  .82 versus .66  .07  106, 44.94  5.21
ersus 2.35  .28  106, 48.67  5.5 versus 2.48 
33  106, respectively; P  .001). Further, when
omparing CD3 subset expansion of the 3 modalities
x vivo engineered in AB/CY, CTCTE and CTECT
ells demonstrated signiﬁcantly increased expansion
hen compared with CTE cells (44.94  5.21 versus
.37  .82  106, 48.67  5.5 versus 7.37  .82 
06, respctively; P  .001).
D3/CD45RO Subset Expansion
CD3/CD45RO represents a memory T cell
hat is signiﬁcantly decreased in unexpanded CB.
herefore, we next evaluated the change in CD3/
D45RO subsets and a signiﬁcant increase was dem-
nstrated in all 3 different modalities (CTE, CTECT,
nd CTCTE) cultured in AB/CY compared with me-
ium alone (38.0  2.4% versus 2.6  .57%, 34.73 
.25% versus 1.87 .25%, 37.62 3.3% versus 2.19
34%, respectively; P  .001). No signiﬁcant differ-
nce in CD3/CD45RO subset expansion was seen
hen comparing the 3 modalities, CTE versus
TCTE versus CTECT, cultured in AB/CY. (
12D8/CD25 Subsets Expansion
After 48 hours in culture with AB/CY, CTE,
TCTE, and CTECT cells demonstrated a signiﬁ-
ant increase (P  .001) in CD8 subset populations
nd CD8/CD25 subsets compared with cells cul-
ured in medium alone (CD8/CD25: 16.2  .6%
ersus 1.14  .08%, 16.5  .7% versus 1.14  .08%,
6.1  .7% versus 1.14  .08%). No signiﬁcant dif-
erences were observed in the CD8 and CD8/25
ubpopulations when comparing the 3 modalities,
TE versus CTCTE versus CTECT, cultured in
B/CY.
D3/CD16/CD56, and
D3/CD56bright/dim/CD16 NK Subset Expansion
CD3/CD16/CD56 represents the majority of
K cells and the 2 large NK subsets include CD3/
D16/CD56bright and CD3/CD16/CD56dim. As
result, we next evaluated the change in CD3/
D16/CD56NK subsets. After 48 hours in culture
ith AB/CY, CTE, CTCTE, and CTECT cells dem-
nstrated a signiﬁcant increase in the CD3/CD16/
D56 subset compared with cells cultured in me-
ium alone (60.2  2.15% versus 47.32  .96%, P 
05; 59.66  2.46% versus 46.67  2.24%, P  .05;
0.83  5.71% versus 45.44  2.43%, P  .01, re-
pectively). Evaluation of CD56bright and CD56dim
xpanded subpopulations in all modalities of CTE,
TCTE, and CTECT demonstrated a signiﬁcant in-
rease in AB/CY combination compared with medium
lone (P  .005; Figure 1). There was a signiﬁcant
ifference in the CD56bright subset in the AB/CY
TE versus CTECT and CTE versus CTCTE (P 
001) but there was no signiﬁcant difference in the
TECT versus CTCTE modality. Further, no sig-
iﬁcant differences were observed in the CD3/
D16/CD56 subpopulations when comparing the
modalities, CTE versus CTCTE versus CTECT,
ultured in AB/CY.
KR Subset Expansion
NK cells can be subdivided by expression of in-
ibiting or activating NKRs. In the following study,
e demonstrated that ex vivo expansion of NK subsets
xpressing CD94/NKG2a was signiﬁcantly in-
reased in all modalities compared with medium alone
P  .003; Figure 2). A signiﬁcant difference was
emonstrated in the AB/CY CTE modality compared
ith CTECT (P  .05) and CTCTE (P  .05). In
ddition, a difference was demonstrated in the AB/CY
TECT method compared with CTCTE (P  .005)
n the CD94/NKG2a subset. NK subsets express-
ng killer immunoglobulin receptors (KIRs) were
oted to be increased in all modalities (CTE,
TECT, and CTCTE) compared with medium aloneFigure 3). A signiﬁcant difference was demonstrated
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Ex Vivo CB NK and LAK Lymphocytes and NK Receptors
Bn the CD56dim/KIR3DL1 subset AB/CY CTE
ompared with CTECT (P  .001) and CTE com-
ared with CTCTE (P  .01). There was also a
ifference in the AB/CY CTECT and CTCTE mo-
alities (P .001). No signiﬁcant difference was dem-
nstrated in the CD56bright/KIR3DL1 subset when
omparing AB/CY CTECT with CTCTE, but there
as a difference in CTE compared with CTECT and
TCTE (P 	 .01).
igure 1. A, CD3/CD16/CD56dim/bright subset expansion as de
nd used as a reference to determine the percentages of CD3/C
erent UCB MNCs from CTE versus CTCTE versus CTECT
epresent mean  SEM (n  3); CD56dim: *P  .05, CTE, CTEC
TECT, CTCTE AB/CY versus medium alone. B, Representative
CB MNCs from CTECT versus CTCTE after 48 hours in cult
opulation was gated and used as a reference to determine CD16/C
erum-free lymphocyte medium.In addition, CD56dim/KIR2DL1/S1 and i
B&MTD56bright/KIR2DL1/S1 subsets were signiﬁ-
antly increased in all modalities compared with me-
ium alone (Figure 4). No signiﬁcant difference was
ound in CD56dim/KIR2DL1/S1 NK subsets in
ny AB/CY modality, but a signiﬁcant difference was
emonstrated in CD56bright/KIR2DL1/S1 recep-
or expression when all AB/CY modalities were com-
ared (P  .05). Further, CD56dim/KIR2DL2 and
D56bright/KIR2DL2 KIR subsets were increased
d by ﬂow cytometry. The CD3 lymphocyte population was gated
D56dim and CD3/CD16/CD56bright expressions of nonad-
hours in culture with AB/CY versus SF medium alone. Results
CTE AB/CY versus medium alone; CD56bright: **P  .01, CTE,
ot of the subset of CD3/CD16/CD56dim/bright in nonadherent
AB/CY as determined by ﬂow cytometry. The CD3 lymphocyte
dim/bright expression. The isotype control was1%. AIMV indicatestermine
D16/C
after 48
T, CT
dot pl
ure in
D56n all modalities compared with medium alone (Figure
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6). However, there was no signiﬁcant difference in
D56dim/KIR2DL2 and CD56bright/KIR2DL2
IR subset expansion within all 3 modalities.
-Helper 1 Cells (IFN-) Expansion
T-helper 1 (Th1) cells expressing IFN- represent
he crucial cell in T-cell mediated tumor cellular cy-
otoxicity. We measured the production of intracellu-
ar IFN- in Th1 subpopulations after cells were
igure 2. A, CD94/NKG2a subset expansion was determined b
reference to determine the percentage of CD94/NKG2a exp
TECT after 48 hours in culture with AB/CY versus SF medium a
ersus medium alone; **P  .006, CTE AB/CY versus medium alon
ot plot of the subset of CD94/NKG2a in nonadherent UCB M
s determined by ﬂow cytometry. The CD16/CD56 populati
xpression. The isotype control was 1%.xed, permeabilized, and stained with IFN-/FITC- A
14onjugated monoclonal antibody. Signiﬁcant increases
n subsets with expression of IFN- were noted in
TE versus CTECT and CTCTE cultured in
B/CY compared with medium alone (9.39  .48%
ersus 3.02 .54%, P .01; 6.92 1.2% versus 2.71
46%, P  .01; 5.81  1.17% versus 2.84  .49%,
	 .05, respectively). Comparable levels of subsets of
ymphocytes with expression of intracellular IFN-
ere observed in all 3 modalities when cultured in
cytometry. The CD16/CD56 population was gated and used as
of nonadherent UCB MNCs from CTE versus CTCTE versus
esults represent mean  SEM (n  3); *P  .012, CTECT AB/CY
 .003, CTCTE AB/CY versus medium alone. B, Representative
rom CTECT versus CTCTE after 48 hours in culture in AB/CY
gated and used as a reference to determine CD94/NKG2ay ﬂow
ression
lone. R
e; ***P
NCs f
on wasB/CY.
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Bell Proliferation
Proliferation of nonadherent CB MNCs after 48
ours in culture was determined by the WST-1 pro-
iferation assay. Use of the CTE, CTCTE, and
TECT methods demonstrated signiﬁcantly in-
reased proliferation when incubated with AB/CY
ersus medium alone (.69  .03, .72  .03, .75  .04
igure 3. A, CD56dim/KIR3DL1 and CD56bright/KIR3DL1
opulation was gated and used as a reference to determine the per
NCs from CTE versus CTCTE versus CTECT after 48 hours in
EM (n  3); CD56dim/KIR3DL1: **P  .024, CTE AB/CY ve
P .04, CTCTE AB/CY versus medium alone; CD56bright/KIR3
nd CTCTE AB/CY versus medium alone. B, Representative dot
NCs from CTECT versus CTCTE after 48 hours in culture in A
as gated and used as a reference to determine CD56dim/bright/KIersus .18 .02, respectively; P  .001). However, no h
B&MTigniﬁcant difference in proliferation was seen when
omparing the 3 modalities, CTE versus CTCTE
ersus CTECT, cultured in AB/CY.
K and LAK Cytotoxicity
NK cytotoxicity of CTE, CTCTE, and CTECT
ells against K562 target tumor cells was signiﬁcantly
expansions as determined by ﬂow cytometry. The CD16/CD56
e of CD56dim/bright/KIR3DL1 expression of nonadherent UCB
e with AB/CY versus SF medium alone. Results represent mean 
edium alone; ***P  .008, CTECT AB/CY versus medium alone;
††P .001, CTE AB/CY versus medium alone; †P .03 CTECT
f the subset of CD56dim/bright/KIR3DL1 in nonadherent UCB
as determined by ﬂow cytometry. The CD16/CD56 population
1 expression. The isotype control was 1%.subset
centag
cultur
rsus m
DL1:
plot o
B/CY
R3DLigher after CTE, CTCTE, and CTECT methods
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6ncubated in AB/CY compared with medium alone
P  .001; AB/CY versus medium alone in CTE,
TCTE, and CTECT, respectively: 52.27  3.5%
ersus 1.97  .44%, 54.03  3.29% versus 6.49 
.02%, and 53.82  3.91%). However, no signiﬁcant
ifferences were seen when comparing the NK cyto-
oxicity against K562 target tumor cells of the 3 mo-
igure 4. A, CD56dim/KIR2DL1/S1 and CD56bright/KIR2DL
D56 population was gated and used as a reference to deter
onadherent UCB MNCs from CTE versus CTCTE versus CTEC
epresent mean SEM (n 3); CD56dim/KIR2DL1/S1: **P .0
1: ††P  .006, CTE; †P  .017, CTECT; †††P  .009, CTCTE
ersus CTCTE AB/CY versus medium alone. B, Representative dot
NCs from CTECT versus CTCTE after 48 hours in culture in A
as gated and used as a reference to determine CD56dim/bright/KIalities cultured in AB/CY. LAK cytotoxicity of CTE, .
16TCTE, and CTECT against Daudi target cells was
igniﬁcantly higher after the CTE, CTCTE, and
TECT methods incubated in AB/CY compared
ith medium alone (P  .001; AB/CY versus medium
lone in CTE, CTCTE, and CTECT, respectively:
1.8  1.8% versus 10.5  1.15%, 27.13  .93%
ersus 12.7  .23, and 29.13  1.03% versus 15.03 
subset expansions as determined by ﬂow cytometry. The CD16/
the percentage of CD56dim/bright/KIR2DL1/S1 expression of
r 48 hours in culture with AB/CY versus SF medium alone. Results
E, CTECT AB/CY versus medium alone; CD56bright/KIR2DL1/
Y versus medium alone; *P  .05, CTE versus CTCTE, CTECT
the subset of CD56dim/bright/KIR2DL1/S1 in nonadherent UCB
as determined by ﬂow cytometry. The CD16/CD56 population
1/S1 expression. The isotype control was 1%.1/S1
mine
T afte
03, CT
AB/C
plot of
B/CY
R2DL77%). However, no signiﬁcant differences were seen
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Bhen comparing the LAK cytotoxicity against Daudi
arget tumor cells of the 3 modalities cultured in AB/CY.
easurement of Cytotoxic Cell Death via Perforin
nd Granzyme B Expression
Granzyme B and perforin are the major mecha-
isms of cellular cytotoxicity. Increased intracellular
igure 5. A, CD56dim/KIR2DL2 and CD56bright/KIR2DL2
opulation was gated and used as a reference to determine the per
NCs from CTE versus CTCTE versus CTECT after 48 hours in
EM (n  3); CD56dim/KIR2DL2: *P  .02, CTE, CTCTE A
lone; CD56bright/KIR2DL2: †P  .02, CTE AB/CY versus me
01, CTCTE AB/CY versus medium alone. B, Representative dot
NCs from CTECT versus CTCTE after 48 hours in culture in A
as gated and used as a reference to determine CD56dim/bright/KIxpression of granzyme B was demonstrated in the v
B&MTB/CY ex vivo expanded CTECT modality (P 
0001) compared with the culture ex vivo expanded in
edium alone (28.52  2.98% versus 1.94  .47%,
espectively). In addition, increased perforin expres-
ion was demonstrated in the AB/CY ex vivo expanded
nd activated CTECT cell cultures (P  .0001) com-
ared with cultures in medium alone (87.1  2.94%
expansions as determined by ﬂow cytometry. The CD16/CD56
e of CD56dim/bright/KIR2DL2 expression of nonadherent UCB
e with AB/CY versus SF medium alone. Results represent mean 
ersus medium alone; **P  .001, CTECT AB/CY versus medium
lone; ††P  .001, CTECT AB/CY versus medium alone; †††P 
f the subset of CD56dim/bright/KIR2DL2 in nonadherent UCB
as determined by ﬂow cytometry. The CD16/CD56 population
2 expression. The isotype control was 1%.subset
centag
cultur
B/CY v
dium a
plot o
B/CYersus 10.0  1.96%, respectively).
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6omparsion of the Three Modalities for Viability
nd Cell Survival
Viability was conﬁrmed by trypan blue (Sigma-
ldrich) exclusion and manual cell counts were per-
ormed with a hemacytometer. The CTE, CTCTE,
nd CTECT cells exhibited similar viabilities (85.0 
.5% versus 85.33 2.6% versus 84.35 4.2%, respec-
ively). Cell survival was assessed by ﬂow cytometry us-
ng annexin V (FITC) and PI. Cells that were early
poptotic were annexin V/PI. Increased survival of
B/CY ex vivo expanded and activated cell cultures dem-
nstrated minimal apoptosis (P  .001) compared with
x vivo expansion in medium alone (CTE: 1.32  .20%
ersus 7.3 .37%; CTECT: 1.07 .32% versus 5.74
49%; CTCTE: 4.53  .26% versus 10.96  .61%,
espectively).
n Vivo Cytotoxicity Studies
K562 tumor engraftment was conﬁrmed in all
nimals by human CD45 expression of circulating
eripheral blood cells as determined by ﬂow cytom-
try (data not shown). Animals receiving 5  106 CB
x vivo expanded in AB/CY (CTECT modality) after
562 injection had 100% mortality at day 7; there-
ore, a higher dose of 1  107 AB/CY cells was used
or subsequent experiments. At days 7 and 14, the
urvival of animals treated with 1  107 AB/CY ex-
anded UCB cells was signiﬁcantly higher than ani-
als that received no treatment (PBS; AB/CY versus
BS: day 7, 100% versus 30%, P  .001; day 14, 90%
ersus 20%, P  .005) and those treated with 1  107
B ex vivo expanded in medium alone (AB/CY versus
edium: day 7, 100% versus 20%, P  .007; day 14,
0% versus 20%, P  .005; Figure 6). Further, me-
ian days of survival after 3 weeks was signiﬁcantly
reater in animals treated with AB/CY expanded UCB
ells compared with PBS or medium alone (AB/CY
ersus PBS: 20 versus 7 days; AB/CY versus media
xpanded UCB cells: 20 versus 7 days; P  .001,
espectively).
ISCUSSION
In this study of ex vivo cellular engineering of CB
ith anti-CD3, IL-2, IL-7, and IL-12, we found sig-
iﬁcant expansion of CB CD3 cells, CD3/45RO
emory cells, and CD8/CD25 T-cell subsets,
D3/CD16/CD56bright/dim NK subsets, NK cell
ubsets expressing activating and inhibiting receptors,
n addition to NK/LAK cytolytic ability. We also
emonstrated that cryopreserved cord blood can be
uccessfully thawed and ex vivo expanded or recryo-
reserved and rethawed after expansion or recryopre-
erved, rethawed, and then successfully ex vivo ex-
anded. The advantage to thaw, ex vivo expansion, A
18nd recryopreservation is that the expanded cells
ould be ready at emergent notice (ie, post-transplant
ymphoproliferative disease (PTLD) or early relapse),
ut the disadvantage would be that more CB would be
x vivo expanded and most would never be used for a
peciﬁc clinical condition. The advantage of thaw,
ecryopreservation, thaw, and ex vivo expansion would
e that only a limited amount of CB would require ex
ivo expansion and only be performed for speciﬁc
linical conditions. The disadvantage would be that it
ay not be available for emergent use because it
equires advance notice and time to ex vivo expand.
ur results indicate that recryopreservation of ex vivo
xpanded CB does not result in a decrease of its
ytolytic functional activity. In contrast, Schmidt-
olf et al [36] demonstrated decreased peripheral
lood (PB) LAK cytotoxicity of cryopreserved cells
ompared with fresh LAK cells. However, Wong et al
37] demonstrated that PB MNCs stimulated with
L-2, IL-7, and/or IL-12 does not induce a decrease in
ytotoxicity in cryopreserved versus fresh cells. Re-
ults similar to our present ex vivo CB immune cell
xpression and activation studies have demonstrated
hat cryopreservation does not impair ex vivo expan-
ion potential, clonogenic ability, or proliferative po-
ential of CB progenitor cells [13,38-40]. Because
ryopreserved CB is generally thawed and washed
efore administration, this may in part have some
ffect on its functional capacity after cryopreservation
31].
Our study also suggests that this short-term ex
ivo engineering system with this AB/CY cocktail ex-
anded CD3 cells in doses that have potential for
igure 6. Effect of UCB ex vivo expanded in medium alone versus
B/CY on survival of NOD/SCID mice that received a xenograft of
562 cells. NOD/SCID mice were injected with 10  106 human
562 cells 3 days after tumor cell injection; groups of mice (n 10)
eceived intraperitoneal injections of CTECT UCB cells (1  107
ells/animal) stimulated with medium alone or CTECT UCB cells
1  107 cells/animal) stimulated with AB/CY. Parallel sham injec-
ions of sterile PBS served as a control group. Injections of ex vivo
xpanded UCB cells or PBS continued every 7 days for 14 days.
umor survival was monitored daily and animals were killed when
hey become moribund with disseminated tumor burden.CCI. Further, this cellular engineering approach en-
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Ex Vivo CB NK and LAK Lymphocytes and NK Receptors
Biched subpopulations of NK cells for prospective
CCI after UCBT. One of the limitations after
CBT has been the inability to treat persistent he-
atologic malignant disease and/or posttransplant
ymphoproliferative disease with DLI after UCBT.
imitations associated with using UCB as a source for
CCI after UCBT include (1) a lack of donor immune
ffector cells from the original cryopreserved UCB
nit, (2) availability of the original donor, and/or (3)
mmaturity of CB cellular immunity. The therapeutic
ose of DLI from matched sibling donors for the
reatment of posttransplant lymphoproliferative dis-
ase and chronic myeloid leukemia after AlloSCT has
een determined to be 1  106 and 1  107 CD3
ells/kg, respectively. The results of our present study
stimate that, for each 5  106 nonadherent MNC
CB aliquot obtained from CTECT or CTCTE,
pproximately 5  107 CD3 cells could be gener-
ted. A standard cryopreserved UCB unit (25 mL)
ontains approximately 750  106 MNCs [31]. A
-aliquot bag has 20- and 5-mL components [8]. By
sing the smaller 5-mL aliquot (20%: 150  106
NCs), the above ex vivo expansion procedure would
ypothetically yield approximately 150  107 CD3
ells. In a 70-kg recipient, this would yield approxi-
ately 2 (1  107 CD3 DLI/kg) aliquots for poten-
ial post-UCBT DLI. These data suggest that a UCB
ryopreserved unit of 4  107 nucleated cells/kg
ould be thawed at the time of UCB transplantation,
ith 80% given to the recipient on day 0 (3.2  107
uc/kg) and the remaining 20% could be ex vivo
xpanded and activated for cytotoxic potential and
ecryopreserved (CTECT) for potential later use for
LI after UCBT. Alternatively, the 20% aliquot
ould be recryopreserved and potentially later re-
hawed and expanded for DLI after UCBT
CTCTE).
Our results demonstrate at least 2 populations of
x vivo engineered UCB immune cells. The ﬁrst
roup appears to be CD3 LAK cells and the second
roup an NK cell (CD3/CD16/CD56) subgroup.
uman NK cells represent approximately 10% of
eripheral blood lymphocytes and are characterized
y a lack of CD3 expression and expression of CD56
bright or dim) and CD16 [22]. NK cells represent a
ajor source of nonspeciﬁc innate cellular immunity,
ave the capability of lysing tumor cells without spe-
iﬁc tumor antigen recognition, and release critically
mportant mediators such as IFN-, tumor necrosis
actor 
, and granulocyte-macrophage colony-form-
ng cells [33,41,42]. The vast majority of the human
K cell population is CD56dim (90%) and expresses
igh levels of CD16 (CD56dim/CD16bright). This
opulation appears to consist of effector cells with
atural and antibody-dependent cytotoxicity capacity
nd requires low doses of IL-2 to be activated
24,43,44]. This population is also characterized by m
B&MTigh levels of expression of the C-lectin receptor
CD94/NKG2) and KIR receptors [25,45]. In com-
arison, CD56bright/CD16dim/CD3 (10%) human
K cell subsets require much higher doses of IL-2 to
ecome cytotoxic and express high levels of C-lectin
CD94/NKG2) but low levels of KIRs [25,26,41]. Our
esults demonstrate a signiﬁcant increase in both sub-
ets of NK CD56 cells including CD56bright and
D56dim.
NK cells in contrast to T cells do not express
eceptors for antigen recognition by T-cell gene re-
eptor rearrangement but bind class I molecules by
K inhibitory or activating NKRs [22]. Two major
lasses of NKRs include the KIRs and C-lectin type.
he NKR KIR family is located on human chromo-
ome 19p13.4 and contains at least 6 inhibitory and 6
ctivating receptors that bind to class I HLAs A, B,
nd C [22,46-49]. Among NKRs, CD94/NKG2A,
IR3DL1, and KIR2DL2 are inhibitory, whereas
IR2DL1/S1 is an activating receptor. Our study
emonstrates that this AB/CY cocktail expands NK
ubsets that express inhibitory and activating recep-
ors. Recent studies have suggested that an NK KIR
ismatch between NK KIR from the cell donor and
ecipient KIR ligand expression after haploidentical
lloSCT in patients with acute myelogenous leukemia
s associated with a signiﬁcant decrease in relapse rate
50,51]. It remains to be determined whether a mis-
atch of activatory or inhibitory KIRs of UCB NK
ells is associated with differences in leukemia relapse
fter UCBT.
The main killing mechanisms of NK and cytotoxic
lymphocytes are mediated by the release of perforin
nd granzymes from intracellular granules onto target
ells [52,53]. Our study demonstrates a strong coex-
ression of perforin and granzyme B after AB/CY ex
ivo expansion when using the CTECT modality.
he poor cytolytic capacity of CD56bright NK cells
ay be due to their weak ability in forming conjugates
ith target cells and low contents of perforin and
ranzymes in their granules [54]. CD56dim cells possess
stronger binding capability to target cells compared
ith CD56bright cells [54]. Because our AB/CY ex
ivo expanded cultures possessed a coexistence of
D56dim and CD56bright subsets, this may explain the
ncreased intracellular expression of perforin and
ranzyme B in this study.
Several studies have suggested that human adult
eripheral blood NK cells may mediate the immune
esponse to human tumor xenografts in animal models
35,55]. Rice et al [39] demonstrated that previous
ryopreservation of ex vivo expanded CB cells is not
etrimental to engraftment as measured in the NOD/
CID mouse model, as we have also demonstrated in
his study. Our study determined the cytotoxicity of
B MNCs ex vivo expanded in 48-hour culture with
edium alone or AB/CY against human tumor mouse
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6enografts. The short-term survival of NOD/SCID
ice xenografted with K562 cells was signiﬁcantly
igher in animals treated with 1  107 UCB cells
xpanded in AB/CY than in animals that received no
reatment or 1  107 UCB cells expanded in medium
lone. Similar results have been reported by Loz-
pone et al [55] who demonstrated a partial but
igniﬁcant inhibition of human melanoma growth
n SCID mice after weekly infusions of activated
K cells selected from peripheral blood. Further
tudies will be required to determine whether this
pproach with ex vivo expanded UCB MNCs can
mprove leukemia disease-free survival after UCBT
n humans.
In summary, this study has demonstrated in short-
erm culture the ability to ex vivo engineer UCB lym-
hocyte subsets including NK and LAK for potential
CCI after UCBT by expanding and recryopreserving
CTECT) or recryopreserving and expanding after re-
hawing (CTCTE) previously cryopreservedUCB at the
ime of initial thaw for UCBT. Our studies have dem-
nstrated 85% viability in addition to augmented cell
urvival with either method and signiﬁcant induction of
roliferative capacity, NK and LAK cytotoxicity, CD3,
D8, and CD3/CD16/CD56 subsets, Th1 subset
xpansion, and CD45RO memory T-cell subsets. There
as also a signiﬁcant enhancement of CD3/CD16/
D56bright and CD3/CD16/CD56dim subsets and
substantial increase in CD56bright and CD56dim/
IR3DL1 NK subsets. A signiﬁcant expansion was seen
n all modalities in the CD56bright and CD56dim/
IR2DL1 subsets when compared with medium alone.
imilarly, the CD94/NKG2a subset was signiﬁcantly
nhanced after CTE, CTECT, and CTCTE. These
ndings may have important implications for the emerg-
ng use of previously cryopreserved UCB cells as an
lternative source of hematopoietic progenitor cells with
n inducible potential for ACCI after UCBT.
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